Table 3: Results of multivariate stepwise analysis for associated factor to SVR.

FactorCategoryPatients with SVR,
no./total (%)
Patients without SVR,
no./total (%)
P value95% CI

Gender
Male98/145 (67.6)47/145 (33.4)0.1141.23 (0.91–2.03)
Female67/98 (68.4)31/98 (31.6)
Age
<40 years93/132 (70.5)39/132 (29.5)0.0931.02 (0.83–1.72)
≥40 years74/111 (66.7)37/111 (33.3)
HCV genotype
Genotype 173/130 (56.2)57/130 (43.8)0.00023.87 (2.16–5.89)
Genotype 2/3/692/113 (81.4)21/113 (18.6)
Absence of cirrhosis
With35/66 (53.0)31/66 (47.0)0.0082.47 (1.36–3.67)
Without130/177 (73.4)47/177 (26.5)
HCV RNA level
<600 IU/mL × 10387/118 (73.7)31/118 (26.3)0.0381.68 (1.12–2.57)
≥600 IU/mL × 10378/125 (62.4)47/125 (37.6)
Peg-IFN α-2a dose
90 μg/week62/93 (66.7)31/93 (33.3)0.1061.31 (0.94–1.81)
180 and135 μg/week103/150 (68.7)47/150 (31.3)

Notes. OR: odds ratio; CI: confidence interval. The association was analyzed by multivariate stepwise analysis included in the model the following preselected variables: peg-IFN α-2a dose of treatment (lower dose versus standard dose), gender (male versus female), age (aged < 40 years versus ≥ 40 years), HCV genotype (genotype 1 versus 2/3/6), absence of cirrhosis(with versus without), and HCV RNA level (<600 IU/mL × 103 versus ≥600 IU/mL × 103).